Immunovant, Inc. had positive results for batoclimab in trials for Myasthenia Gravis & CIDP; Thyroid Eye Disease data ...

One type, the immune-mediated demyelinating neuropathies, includes Guillain-Barré syndrome (GBS), chronic inflammatory demyelinating polyneuropathy (CIDP), multifocal motor neuropathy (MMN), and ...

The company plans to use results from its Phase III myasthenia gravis study to support its pipeline candidate IMVT-1402 over ...

Plans to develop S-1117 for treatment of wide array of IgG autoantibody-driven diseases, such as myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, and immune thrombocytopenia ...

chronic inflammatory demyelinating polyneuropathy, and immune thrombocytopenia. “The start of our first-in-human study of S‑1117 marks a significant milestone for Seismic as we transition to a ...

immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren ...

(NASDAQ:ARGX – Get Free Report) was upgraded by investment analysts at Sanford C. Bernstein from a “market perform” rating to ...

Immunovant and Roivant Sciences said Wednesday their rare disease drug succeeded in a final-phase study, but the duo won't seek approval.

House: Johnson & Johnson has received Fast Track designation (FTD) from the U.S. Food and Drug Administration (FDA) for ...

Spring House, Pennsylvania Wednesday, March 19, 2025, 14:00 Hrs [IST] ...

Chronic inflammatory demyelinating polyneuropathy (CIDP) and Guillain-Barré syndrome (GBS) are immune-mediated neuropathies. Their pathogenesis involves an immune response to non-protein antigens, ...